Medidata Supports White House Cancer Moonshot Effort with its Patient Cloud Technologies

New York–July 27, 2022–Medidata, a Dassault Systèmes company, is supporting the White House Cancer Moonshot initiative by working with the National Cancer Institute (NCI) to enroll patients in the Cancer Moonshot Biobank. The Biobank is a project designed to better understand how cancer develops and grows, and why some cancers stop responding to treatment. People with cancer are asked to donate tumor tissue, blood samples, and health data to find discoveries that improve cancer treatments and increase survival.

Medidata, Theradex Oncology, and NCI are helping enroll patients in the Biobank across more than 100 clinical sites in the U.S. This team works together to engage and educate study volunteers, accurately and securely collect patient information in the clinical trial, and enroll patients in the project. The enrollment process includes clinical site staff providing orientation content and related HIPAA (Health Insurance Portability and Accountability Act privacy law) documents to the patient for education and eSignature. 

These activities are part of the White House Cancer Moonshot initiative, which has set a goal of reducing the cancer death rate by 50% over the next 25 years, and improving the experience of people and their families living with and surviving cancer.

“We won’t reach the goals of the Cancer Moonshot without gathering a rich set of data for researchers, and that requires attracting a diverse and expansive patient population to participate,” said Peter Clark, director, NCI Rave Development at Theradex Oncology, a CRO providing cancer clinical trial services. “Once a patient has agreed to participate, keeping them comfortable and facilitating an easy enrollment are important, and we appreciate the assistance we have received from the Medidata team in supporting this.” 

The Cancer Moonshot Biobank relies on Medidata’s Patient Cloud and Rave solutions, including eConsent and Rave EDC (electronic data capture). eConsent is an innovative, regulatory-compliant, patient-friendly, electronic consent system for clinical trials. Rave EDC (electronic data capture) is the most advanced, robust, and secure system for clinical trial site, patient, and lab data capture and management.

“We are proud to be part of supporting this important initiative,” said David Geismar, senior vice president, Professional Services at Medidata. “Helping enroll patients with eConsent and managing patient data with Rave EDC are important pieces of the overall  Cancer Moonshot Biobank effort to accelerate progress in treating cancer and helping patients with cancer live longer.”

Medidata currently supports more than 2,000 clinical trials in the government, academic, and not-for-profit sectors. Medidata’s commitment to these sectors extends from providing the industry-leading Rave EDC to innovative patient-facing technologies like eConsent and more.

To learn more about the Cancer Moonshot Biobank and how to participate, visit

Medidata is a wholly-owned subsidiary of Dassault Systèmes, which with its 3DEXPERIENCE platform is positioned to lead the digital transformation of life sciences in the age of personalized medicine with the first end-to-end scientific and business platform, from research to commercialization.

About Medidata

Medidata is powering smarter treatments and healthier people through digital solutions to support clinical trials. Celebrating 25 years of ground-breaking technological innovation across more than 33,000 trials and 10 million patients, Medidata offers industry-leading expertise, analytics-powered insights, and the largest patient-level historical clinical trial data set in the world. More than 1 million registered users across 2,200+ customers trust Medidata’s seamless, end-to-end platform to improve patient experiences, accelerate clinical breakthroughs, and bring therapies to market faster. A Dassault Systèmes brand (Euronext Paris: FR0014003TT8, DSY.PA), Medidata is headquartered in New York City and has been recognized as a Leader by Everest Group and IDC. Discover more at and follow us @Medidata.

About Dassault Systèmes

Dassault Systèmes is a catalyst for human progress. We provide business and people with collaborative virtual environments to imagine sustainable innovations. By creating virtual twin experiences of the real world with our 3DEXPERIENCE platform and applications, our customers can redefine the creation, production and life-cycle-management processes of their offer and thus have a meaningful impact to make the world more sustainable. The beauty of the Experience Economy is that it is a human-centered economy for the benefit of all – consumers, patients and citizens. Dassault Systèmes brings value to more than 350,000 customers of all sizes, in all industries, in more than 150 countries. For more information, visit